NCT06840054 · Phase 2 · NOT YET RECRUITING
The Safety and Efficacy of Sodium Pentaborate Pentahydrate in Patients With Mild to Moderate Alzheimer's Disease
This trial is testing whether sodium pentaborate pentahydrate, a boron-based compound, can slow cognitive and functional decline in people already diagnosed with mild to moderate Alzheimer's disease. Participants take either the compound or a placebo alongside their existing Donepezil. Researchers will track thinking and daily living scores over six months. This is a Phase 2 trial, meaning it is exploring whether the drug works and is safe, not yet proven or approved.
Eligibility criteria
Inclusion Criteria: Age between 55 and 85 years Diagnosis of mild to moderate Alzheimer's disease based on the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria Mini-Mental State Examination (MMSE) score between 10 and 24 Evidence of episodic memory impairment (≥1 standard deviation below age norm) Use of stable doses of Alzheimer's medications Exclusion Criteria: Presence of major neurological or psychiatric disorders Significant amyloid-related imaging abnormalities (ARIA) detected on magnetic resonance imaging (MRI) Recent use of experimental drugs
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-02-21